BeiGene Granted Second China Priority Review for PD-1 Candidate

02:22 EDT 9 Jul 2019 | ChinaBio Today

BeiGene of Beijing has been granted priority review by the NMPA for tislelizumab, the company's PD-1 immunotherapy, as a treatment for urothelial carcinoma (UC), the most common form of bladder cancer. It is the second indication to receive priority review. In November 2018, the NMPA agreed to review the candidate under priority rules for relapsed/refractory (R/R) classic Hodgkin’s lymphoma (cHL). BeiGene said it is testing tislelizumab in 13 pivotal or potentially registration-enabling trials. More details....

Stock Symbols: (NSDQ: BGNE; HKEX: 06160)

Share this with colleagues:

Original Article: BeiGene Granted Second China Priority Review for PD-1 Candidate


More From BioPortfolio on "BeiGene Granted Second China Priority Review for PD-1 Candidate"

Quick Search


Relevant Topics

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...